I am a
Home I AM A Search Login

Papers of the Week

Papers: 28 May 2022 - 3 Jun 2022

Human Studies, Pharmacology/Drug Development

2022 May 28




Editor's Pick

Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.


D'haens G, Panaccione R, Baert F, Bossuyt P, Colombel J-F, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, et al.
Lancet. 2022 May 28; 399(10340):2015-2030.
PMID: 35644154.


Risankizumab, an interleukin (IL)-23 p19 inhibitor, was evaluated for safety and efficacy as induction therapy in patients with moderately to severely active Crohn's disease.